For Immediate Release |
3 August 2009 |
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Notification of Interim Results
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, will announce its interim results for the six months ended 30 June 2009 on Tuesday 8 September 2009.
A briefing for analysts will be held at 9.30am on the day of the results at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
For further information, please contact:
Advanced Medical Solutions Group plc |
|
Don Evans, Chief Executive Officer Mary Tavener, Finance Director |
Tel: +44 (0) 1606 545508 |
Buchanan Communications |
|
Mark Court / Stasa Filiplic |
Tel: +44 (0) 20 7466 5000 |
Investec Bank plc |
Tel: +44 (0) 20 7597 5970 |
Richard Jones / Tim Pratelli |
Notes to Editors:
Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.
Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.
The advanced woundcare products are based on the moist wound healing principle. AMS uses its inhouse technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.
The acquisition of a 49.4% stake in Corpura BV in May 2008 strengthened AMS’s position in hydrophilic polyurethane foam – the largest and fastest growing segment of the advanced woundcare market.
AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection.
AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors.
This information is provided by RNS
END
NOREFLFXKDBEBBQ